Everytime Enveda shows up on the #NYSE it brings chills.
Thanks to Eric J. Dimise, PhD and the entire NYSE team for your support! Not just for #Enveda, but for #Nature, #AI, and making #medicines that matter.
#Enveda, led by our #CEO Viswa Colluru, PhD, has produced strong results with its first-ever #clinical readout.
Enveda’s once-daily oral drug #ENV-294 reduced a commonly used #eczema #severity score by an average of 68% after a month of treatment.
Read more
endpoints.news/envedas-firs...
We’re honored to see #Enveda recognized among Fast Company's Most Innovative Companies. We believe the next era of drug discovery won’t be invented. Instead, it will be uncovered. Cannot wait see where our CEO at helm Dr. Viswa Colluru takes us next! 🚀 Read: https://www.fastcompany.
We’re honored to see #Enveda recognized among Fast Company's Most #Innovative Companies.
We believe the next era of drug discovery won’t be invented. Instead, it will be uncovered.
Cannot wait see where our #CEO at helm Dr. Viswa Colluru takes us next! 🚀
Read: www.fastcompany.com/91497087/bio...
We have received 𝗮𝗻𝗼𝘁𝗵𝗲𝗿 FDA #IND clearance and have initiated Phase 1 for ENV-6946, bringing our total to three first-in-class, novel, nature-inspired molecules in the clinic.
ENV-6946 is an oral small molecule engineered for the potential to treat inflammatory bowel disease!! #IBD #Enveda #drug
We are proud to announce our latest milestone at #Enveda:
#𝗙𝗗𝗔 𝗜𝗡𝗗 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 𝗮𝗻𝗱 𝗳𝗶𝗿𝘀𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗱𝗼𝘀𝗲𝗱 for 𝗘𝗡𝗩-𝟯𝟬𝟴, our first-in-class #oral therapy for #obesity.
ENV-308 is a once-daily oral small molecule designed with exciting potential for 𝗱𝘂𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝘁𝗼𝗹𝗲𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝗮𝗻𝗱 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝘂𝘀𝗲.
We are excited to welcome Nadeem Sarwar to #Enveda as 𝗦𝗩𝗣 & 𝗚𝗹𝗼𝗯𝗮𝗹 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 #𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 #𝗗𝗶𝘀𝗲𝗮𝘀𝗲 #𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆.
Nadeem brings rare experience from the front lines of metabolic medicine, as the former Co-Founder and Head of the #Transformational Prevention Unit at Novo Nordisk !
Additional $$$ Raises: #CrusoeEnergySystems $175M Debt; #Baseten $150M Series D; #Enveda $150M Series D;
#XSquareRobot $140M; #HarborHealth $130M Series B; #Speedchain $111M Equity & Debt; #Aven $110M Series E; #CuspAI $100M Series A; #Nuro $97M Series A
No fresh tuna or barrilete until August 8 along the entire Pacific Coast of Mexico. #OutOfSeason #EnVeda #Zihuatanejo #Atún
Funding Raises: #Skydio $170M Series E extension; #Enveda $130M Series C; #Enfabrica $115M Series C; #Tessl $100M Series A; #Tekever €70M Series B; #Rox $50M Series A; #PickleRobotCompany $50M Series B; #Federato $40M Series C; #TelehealthConferenceCenter €20M Series A
